What is Jasper Therapeutics, Inc. (JSPRW)?

Jasper Therapeutics, Inc. (JSPRW) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of JSPRW?

The current price of JSPRW is $0.00. Prices are updated in real time on Stocks360.

What is JSPRW's price-to-earnings (PE) ratio?

JSPRW's trailing twelve-month PE ratio is -0.00, based on current price and earnings per share data available on Stocks360.

What is JSPRW's market capitalization?

JSPRW's market capitalization is $3,251.00, placing it in the small-cap tier.

Jasper Therapeutics, Inc. (JSPRW)

Stock analysis · NASDAQ · Healthcare · Biotechnology

$0.00

Market Cap

$3.25K

PE (TTM)

-0.00

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

3.00

Day Range

$0.00 – $0.08

52-wk Range

$0.00 – $0.08

Avg Volume

N/A

Volume

863.07K

Jasper Therapeutics, Inc. (JSPRW) is a publicly traded company in the Healthcare sector. Latest price: $0.00. Market cap $3.25K. Trailing PE -0.00. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

1-Year Price

2025-10-31 · $0.10 2026-09-24 · $0.00 (-99.80%)

Earnings

Most Recent

Aug 14, 2026

EPS $-0.10 vs est. $-0.27

Beat by $0.17

Next Earnings

Nov 5, 2026

EPS estimate $-0.08

Proprietary Signals

Signal snapshot temporarily unavailable.

About Jasper Therapeutics, Inc.

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company's lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma, as well as conditioning agents for stem cell transplant in patients with sickle cell disease, Fanconi anemia, and severe combined immunodeficiency. Jasper Therapeutics, Inc. was founded in 2018 and is based in Redwood City, California.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-0.00×
P/S (TTM)	0.00×
P/B	0.00×
P/FCF (TTM)	-0.00×
EV / EBITDA	0.16×
EV / Sales	0.00×
Earnings Yield	-505472.06%
Free Cash Flow Yield	-1164314.86%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	-$7.04M
Net Income (TTM)	-$16.43M
Free Cash Flow (TTM)	-$37.85M
Net Debt	-$7.04M
Working Capital	$3.73M
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Return on Equity	-565.10%
Return on Invested Capital	-1225.43%